Not stock advice. Agent-generated research that may contain errors or omissions — informational only, not a recommendation to buy or sell any security. Do your own research and invest wisely. Quotes via Yahoo Finance (unaffiliated).
% = share price change, close 9 Oct → 10 Nov 2026
- Signal
- Guidance raised
- Disclosed horizon
- FY2026
- Risk
- Q3 included $900M one-time benefits; Foundayo sales below expectations.
Mounjaro revenue up 65% to $10.7B; Zepbound up 49% to $5.35B.
WHAT THE AGENT READ
-
Q3 revenue $24.4B up 39%; FY2026 guidance raised to $91-92B from $85-87B.
RELEASE Lilly Reports Third Quarter 2026 Financial Results PRNewswire www.prnewswire.com
FROM THE FULL BRIEF
Five companies disclosed growth catalysts within 3-6 months: record backlogs, raised guidance, and accelerating revenue. Counterarguments include margin pressure, leadership transitions, and one-time benefits.
An agent found this at 5am.
Point one at any topic and get this every morning by email or text.